Literature DB >> 21384508

Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates.

Daniela E Oprea-Lager1, Bastiaan J Sorgdrager, J Wouter Jukema, Roderick W C Scherptong, Jan Ringers, Minneke J Coenraad, Bart van Hoek, Marcel P M Stokkel.   

Abstract

A cardiac evaluation before orthotopic liver transplantation (OLT) is imperative. Previous investigations have demonstrated that mild to moderate reversible perfusion defects on myocardial perfusion scintigraphy (MPS) in general are associated with a low risk for perioperative cardiac events. The objective of this study was to assess any perfusion defects in consecutive patients with chronic liver disease who were undergoing OLT. OLT candidates underwent extensive cardiovascular screening that included, among other methods, MPS. Patients who had no contraindications for surgery and underwent OLT were followed up. The occurrence and risk of complications and mortality were compared in 3 groups of patients: patients with normal MPS results, patients with any reversible defect, and patients with a fixed perfusion defect on MPS. In all, 156 subsequent patients underwent OLT. One or more reversible segmental perfusion defects on MPS were present in 14 patients (<3 segments, n = 12; 3 segments without obstructive coronary artery disease, n = 2). The risk of complications did not differ significantly between patients with normal MPS findings and patients with a reversible perfusion defect (odds ratio = 3.04, 95% confidence interval = 0.65-14.26, P = 0.16), although the study was not sufficiently powered to show a difference. The presence of 1 or more reversible defects on MPS was significantly associated with an increased incidence of all-cause 1-year mortality (hazard ratio = 3.17, 95% confidence interval = 1.02-9.83, P = 0.046). No significant difference in the outcomes of patients with normal MPS findings and patients with a fixed defect on MPS was found; the study was, however, not adequately powered to do so. In conclusion, the results of this small cohort study indicate that patients with mild to moderate reversible perfusion defects on MPS may have inferior survival characteristics in comparison with patients with normal MPS results. A prospective, adequately powered study is required to confirm the results of this study.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21384508     DOI: 10.1002/lt.22234

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  5 in total

Review 1.  Incidence of and Risk Assessment for Adverse Cardiovascular Outcomes After Liver Transplantation: A Systematic Review.

Authors:  Monica A Konerman; Danielle Fritze; Richard L Weinberg; Christopher J Sonnenday; Pratima Sharma
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

Review 2.  Cardiac imaging for the assessment of patients being evaluated for liver transplantation.

Authors:  Kameel Kassab; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2021-04-06       Impact factor: 3.872

Review 3.  Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.

Authors:  Giuseppina Pisano; Anna L Fracanzani; Lucio Caccamo; Maria F Donato; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

4.  Significance of Abnormal Myocardial Perfusion Scans in Candidates for Orthotopic Liver Transplantation.

Authors:  Atefe Esmaili; Saeed Farzanefar; Alireza Emami-Ardakani; Mehrshad Abbasi
Journal:  J Tehran Heart Cent       Date:  2017-01

5.  Cardiac stress testing and coronary artery disease in liver transplantation candidates: Meta-analysis.

Authors:  Jonathan Soldera; Fábio Camazzola; Santiago Rodríguez; Ajacio Brandão
Journal:  World J Hepatol       Date:  2018-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.